Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
2. Ft-2102
1. 1887014-12-1
2. Ft-2102
3. Olutasidenib [usan]
4. Olutasidenib (ft-2102)
5. 0t4imt8s5z
6. 5-[[(1s)-1-(6-chloro-2-oxo-1h-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
7. (s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
8. Ft2102
9. 2-pyridinecarbonitrile, 5-(((1s)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-
10. 5-(((1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
11. 5-{[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
12. 5-[[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
13. Olutasidenib [inn]
14. Unii-0t4imt8s5z
15. Olutasidenib [who-dd]
16. Chembl4297610
17. Schembl17603134
18. Gtpl10319
19. Amy16919
20. Ex-a4523
21. Bdbm50506474
22. Example 26 [us9834539b2]
23. Nsc818621
24. S8949
25. Ft-2102ft-2102
26. Nsc-818621
27. Ac-36556
28. Hy-114226
29. Cs-0080183
30. D87221
31. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
32. Pwv
Molecular Weight | 354.8 g/mol |
---|---|
Molecular Formula | C18H15ClN4O2 |
XLogP3 | 2.5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 354.0883534 g/mol |
Monoisotopic Mass | 354.0883534 g/mol |
Topological Polar Surface Area | 85.2 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 745 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Patents & EXCLUSIVITIES
Patent Expiration Date : 2039-07-17
US Patent Number : 11738018
Drug Substance Claim :
Drug Product Claim :
Application Number : 215814
Patent Use Code : U-3684
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-07-17
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 10532047
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 215814
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 12053463
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 215814
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 10959994
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215814
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 11497743
Drug Substance Claim :
Drug Product Claim :
Application Number : 215814
Patent Use Code : U-3495
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2035-09-18
US Patent Number : 10414752
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215814
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 11376246
Drug Substance Claim :
Drug Product Claim :
Application Number : 215814
Patent Use Code : U-3495
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2035-09-18
US Patent Number : 10550098
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 215814
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 11013734
Drug Substance Claim :
Drug Product Claim :
Application Number : 215814
Patent Use Code : U-3495
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2039-05-16
US Patent Number : 11013733
Drug Substance Claim :
Drug Product Claim :
Application Number : 215814
Patent Use Code : U-3496
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-05-16
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
ABOUT THIS PAGE
A Olutasidenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olutasidenib, including repackagers and relabelers. The FDA regulates Olutasidenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olutasidenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Olutasidenib supplier is an individual or a company that provides Olutasidenib active pharmaceutical ingredient (API) or Olutasidenib finished formulations upon request. The Olutasidenib suppliers may include Olutasidenib API manufacturers, exporters, distributors and traders.
Olutasidenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olutasidenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olutasidenib GMP manufacturer or Olutasidenib GMP API supplier for your needs.
A Olutasidenib CoA (Certificate of Analysis) is a formal document that attests to Olutasidenib's compliance with Olutasidenib specifications and serves as a tool for batch-level quality control.
Olutasidenib CoA mostly includes findings from lab analyses of a specific batch. For each Olutasidenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olutasidenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olutasidenib EP), Olutasidenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olutasidenib USP).
LOOKING FOR A SUPPLIER?